Acumen Pharmaceuticals Inc (ABOS) — Cash Flow-to-Debt Ratio
Acumen Pharmaceuticals Inc (ABOS) has a Cash Flow-to-Debt Ratio of -0.36x as of December 2025, meaning its operating cash flow of $-19.10 Million could theoretically repay 0% of its total liabilities ($52.40 Million) in one year. See Acumen Pharmaceuticals Inc (ABOS) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Acumen Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Acumen Pharmaceuticals Inc across 7 annual periods. Also explore how fast is Acumen Pharmaceuticals Inc growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Acumen Pharmaceuticals Inc (2019–2025)
Year-by-year debt coverage analysis for Acumen Pharmaceuticals Inc. For market capitalisation and broader financial context, see Acumen Pharmaceuticals Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.20x | $-115.54 Million | $52.40 Million | ▼ -46.2% |
| 2024 | -1.51x | $-86.22 Million | $57.18 Million | ▼ -51.1% |
| 2023 | -1.00x | $-43.06 Million | $43.15 Million | ▲ +77.8% |
| 2022 | -4.50x | $-35.15 Million | $7.81 Million | ▼ -29.0% |
| 2021 | -3.49x | $-17.96 Million | $5.15 Million | ▼ -2851.9% |
| 2020 | -0.12x | $-7.45 Million | $63.02 Million | ▲ +67.5% |
| 2019 | -0.36x | $-6.82 Million | $18.74 Million | — |